Kiora Pharmaceuticals (KPRX) News Today $3.00 -0.01 (-0.33%) Closing price 04:00 PM EasternExtended Trading$3.02 +0.02 (+0.50%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.8% Higher - What's Next?July 9 at 2:55 AM | americanbankingnews.comkiora pharmaceuticals reports results of annual shareholder meetingJune 6, 2025 | investing.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in AsiaJune 3, 2025 | finanznachrichten.deKiora Pharmaceuticals Reports Q1 2025 Financial ResultsMay 30, 2025 | tipranks.comKiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative VitreoretinopathyMay 5, 2025 | finance.yahoo.comKiora Pharmaceuticals Advances Retinal Disease PipelineMarch 25, 2025 | tipranks.comKiora Pharmaceuticals secures new patent for KIO-104February 13, 2025 | msn.comWe Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be ConservativeNovember 15, 2024 | finance.yahoo.comKiora Pharmaceuticals’ Promising Growth Prospects: Buy Rating Backed by Clinical Advancements and Strong Financial PositionNovember 12, 2024 | markets.businessinsider.comPositive Developments and Strategic Partnerships Propel Kiora Pharmaceuticals to a Buy RatingNovember 1, 2024 | markets.businessinsider.comKiora Pharmaceuticals Gains Approval for Phase 2 TrialOctober 29, 2024 | markets.businessinsider.comKiora Pharmaceuticals (NASDAQ:KPRX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comKiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Aron Shapiro Buys 3,000 SharesSeptember 12, 2024 | insidertrades.comBuy Rating on Kiora Pharmaceuticals Amid Promising Clinical Trials and Strong FinancialsAugust 23, 2024 | markets.businessinsider.comBuy Rating on Kiora Pharmaceuticals: Strong Financials and Promising KIO-301 ProgressAugust 10, 2024 | markets.businessinsider.comKiora Pharmaceuticals Inc (7EY0.MU)August 8, 2024 | nz.finance.yahoo.comBrian M. Strem Buys 3,000 Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) StockJune 15, 2024 | insidertrades.comKiora Pharmaceuticals, Inc. (NASDAQ:KPRX) CEO Brian M. Strem Acquires 3,000 SharesJune 13, 2024 | marketbeat.comKiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest UpdateJune 12, 2024 | marketbeat.comBuy Rating for Kiora Pharmaceuticals Bolstered by Strong Financials and Promising Clinical Trial DataMay 20, 2024 | markets.businessinsider.comKiora Pharmaceuticals, Inc. (KPRX)May 18, 2024 | finance.yahoo.comBuy Rating on Kiora Pharmaceuticals Amid Strong Financials and Promising Clinical TrialsMay 11, 2024 | markets.businessinsider.comKPRX Stock Earnings: Kiora Pharmaceuticals Beats EPS for Q1 2024May 10, 2024 | investorplace.comKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal DiseaseMay 10, 2024 | finanznachrichten.deKiora Pharmaceuticals reports FY resultsMarch 25, 2024 | msn.comKiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial ResultsFebruary 9, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To KnowFebruary 9, 2024 | markets.businessinsider.comWhat's Going On With Kiora Pharmaceuticals Stock?February 1, 2024 | msn.comWhy Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketFebruary 1, 2024 | benzinga.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?February 1, 2024 | msn.comKiora stock soars after hours on deal with Thea Open InnovationJanuary 31, 2024 | msn.comKiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial RoyaltiesJanuary 31, 2024 | finance.yahoo.comKiora Pharmaceuticals Announces Private Placement of up to Approximately $45 MillionJanuary 31, 2024 | finance.yahoo.comKiora Pharmaceuticals (Nasdaq:KPRX) HeadlineTrading was temporarily halted for "KPRX" at 05:01 PM with a stated reason of "News pending."...January 31, 2024 | marketbeat.comKiora Pharmaceuticals Inc KPRXJanuary 9, 2024 | morningstar.comMBreaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301November 17, 2023 | finance.yahoo.comKiora Pharmaceuticals Stock (NASDAQ:KPRX) Earnings Dates and Earning CallsNovember 11, 2023 | benzinga.comKiora Pharmaceuticals reports Q3 resultsNovember 9, 2023 | msn.comKiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis PigmentosaNovember 9, 2023 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)November 7, 2023 | markets.businessinsider.comAnalyst Expectations for Kiora Pharmaceuticals's FutureNovember 6, 2023 | markets.businessinsider.comAAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis PigmentosaNovember 4, 2023 | finance.yahoo.comKiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor ConferenceOctober 16, 2023 | finance.yahoo.comKiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis PigmentosaOctober 3, 2023 | finance.yahoo.comKiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 YearsSeptember 21, 2023 | finance.yahoo.comKiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis PigmentosaSeptember 18, 2023 | finance.yahoo.comKiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis PigmentosaSeptember 14, 2023 | finance.yahoo.comKiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27September 1, 2023 | finance.yahoo.comKiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal DiseasesAugust 29, 2023 | finance.yahoo.comIs Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation AnalysisAugust 24, 2023 | finance.yahoo.com Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address KPRX Media Mentions By Week KPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPRX News Sentiment▼0.930.99▲Average Medical News Sentiment KPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPRX Articles This Week▼20▲KPRX Articles Average Week Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Telomir Pharmaceuticals News Today Kezar Life Sciences News Today Rein Therapeutics News Today KALA BIO News Today OnKure Therapeutics News Today Estrella Immunopharma News Today Biodexa Pharmaceuticals News Today Rani Therapeutics News Today Marinus Pharmaceuticals News Today Synergy CHC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPRX) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KPRX Stock Alerts